Tugas Softskill

Sejarah, Visi,  Misi dan Perkembangan PT Bayer

Bayer AG  adalah sebuah perusahaan kimia dan farmasi Jerman yang didirikan pada tahun 1863 oleh Friedrich Bayer yang bermarkas di Leverkusen, North Rhine-Westphalia, Jerman. Perusahaan ini terkenal dengan aspirinnya, produk lain yang di produksi oleh PT Bayer adalah obat hewan, obat generik dan khusus, produk kesehatan wanita, obat bebas, produk penderita diabetes, pestisida, bioteknologi tanaman, polimer, lem dll

Anak perusahaan PT Bayer diantaranya adalah Bayer MaterialScience, Bayer USA, Bayer Schering Pharma, Bayer HealthCare Pharmaceuticals, Bayer CropScience. DiIndonesia, lisensi produk-produk buatan Bayer dipegang oleh PT Bayer Indonesia. PT.Bayer Indonesia merupakan perusahaan swasta yang bergerak di bidang obat-obatan, didirikan pada tanggal 14 Maret 1969 dengan akte notaris atas nama Elisa Pondang nomor 20 yang disahkan oleh Menteri Kehakiman No. 7A5. 32. 25 tertanggal 25 Maret 1969.

Pada tahun 1969, PT Bayer Indonesia hanya berfungsi sebagai distributor produksi obat-obatan perusahaan Bayer negara lainya.  Pada tahun 1971 PT Bayer Indonesia mulai memproduksi obat-obatan yang digunakan untuk manusia dengan nama PT Bayer Pharma Indonesia yang berlokasi di Jalan Raya Bogor Km 28, Cibubur. Pada tanggal 1972, PT Bayer Pharma Indonesia mengembangkan usahanya dengan mendirikan PT Bayer Agro Chemical yang memproduksi obat-obatan serangga seperti insektisida, pestisida, dan lain-lain. PT Bayer Agro Chemical ini berlokasi di Kawasan Industri Pulo Gadung.

Pada tahun 1981, PT Bayer Pharma Indonesia dan PT Bayer Agro Chemical semakin berkembang dan mendirikan  PT Bayer Anyer Chemical di Gresik, Jawa Timur (sekarang sudah ditutup). PT Bayer Anyer Chemical ini memproduksi bahan-bahan makanan ternak, obat-obatan untuk ternak, dan bahan baku obat yang diperlukan PT Bayer Pharma Indonesia (misalnya asetosal dan piperazin).

Pada bulan Mei 1982, dilakukan penggabungan (merger) antara PT Bayer Pharma Indonesia, PT Bayer Agro Chemical, dan PT Bayer Anyer Chemical sehingga berubah menjadi PT Bayer Indonesia yang berlokasi di Cibubur, Jakarta Timur sampai sekarang.

Tahun 1982, perseroan melakukan “go public” dan menawarkan sahamnya di Bursa Efek Jakarta (BEJ). Tahun 1997, PT Bayer Indonesia berubah nama menjadi PT Bayer Indonesia Tbk. Pada tahun 1998 PT Bayer Indonesia Tbk. mendapat sertifikat ISO 9002.

Tanggal 31 Desember 2002, PT Bayer Indonesia Tbk. melakukan divestasi usaha produk kesehatan rumah tangga setelah pemegang saham PT Bayer Indonesia Tbk. menyetujui penjualan produk kesehatan rumah tangga kepada PT Johnson Home Hygiene Products pada Rapat Umum Pemegang Saham Luar Biasa (RUPSLB).

Pada saat yang sama perseroan membeli seluruh saham PT Aventis Crop Science Indonesia. Penggabungan usaha agro kimia dua perusahaan tersebut telah menempatan perseroan di jajaran atas pemimpin pasar.

Pada tanggal 3 Januari 2005, PT Bayer Indonesia membeli PT Roche divisi OTC. Sekarang PT Bayer Indonesia mempunyai dua buah pabrik yang memproduksi obat-obatan. Pabrik tersebut berlokasi di Cibubur dan Cimanggis yang sampai kini dikenal dengan pabrik Bayer Cibubur dan pabrik Bayer Cimanggis.

Komitmen PT Bayer Indonesia sebagai salah satu perusahaan yang melaksanakan pembangunan berkelanjutan (sustainable development) kembali ditunjukkan dengan menyelenggarakan salah satu program bagi generasi muda untuk memberikan kontribusi terutama dalam bidang pelestarian lingkungan yaitu Bayer Young Enviromental Envoy (BYEE).

Program BYEE merupakan hasil kerjasama antara Bayer dengan United Nations Environment Programme (UNEP) untuk mendukung generasi muda dalam berkomitmen terhadap aktifitas perlindungan lingkungan.

Visi : Terdapat di dalam slogan Bayer: Ilmu Untuk Sebuah Kehidupan Yang Lebih Baik

Misi :  1. Untuk menjadi perusahaan global yang inovatif di bidang farmasi dan medis, serta bidang pertanian, serta bidang material.

2.Untuk menjadi perusahaan yang mempunyai sumber daya manusia yang mempunyai kompetensi dan motivasi yang tinggi sehingga mampu diandalkan, mempunyai teknologi yang unggul sedunia sehingga menunjang di dalam rangka mengembangkan inovasi, mempunyai produk yang bermutu tinggi, serta mempunyai penyediaan pelayanan yang sempurna bagi kehidupan khususnya kehidupan manusia

Laporan Keuangan :

	Note	2013	2014
		€ million	€ million
Net sales	[7]	40,157	42,239
Cost of goods sold		(19,516)	(20,266)
Gross profit		20,641	21,973
Selling expenses	[8]	(10,312)	(11,018)
Research and development expenses	[9]	(3,406)	(3,574)
General administration expenses		(1,712)	(1,741)
Other operating income	[10]	887	716
Other operating expenses	[11]	(1,164)	(850)
EBIT1		4,934	5,506
Equity-method loss	[13.1]	(16)	(13)
Financial income		389	343
Financial expenses		(1,100)	(1,311)
Financial result	[13]	(727)	(981)
Income before income taxes		4,207	4,525
Income taxes	[14]	(1,021)	(1,082)
Income after income taxes		3,186	3,443
of which attributable to non-controlling interest	[15]	(3)	17
of which attributable to Bayer AG stockholders (net income)		3,189	3,426
		€	€
Earnings per share	[16]
Basic		3.86	4.14
Diluted		3.86	4.14
2013 figures restated 1 EBIT: earnings before financial result and taxes    [Table 4.2] Note 2013 2014 € million € million Income after income taxes 3,186 3,443 of which attributable to non-controlling interest [15] (3) 17 of which attributable to Bayer AG stockholders 3,189 3,426 Remeasurements of the net defined benefit liability for post-employment benefit plans [25] 1,946 (5,159) Income taxes [14] (604) 1,621 Other comprehensive income from remeasurements of the net defined benefit liability for post-employment benefit plans 1,342 (3,538) Other comprehensive income that will not be reclassified subsequently to profit or loss 1,342 (3,538) Changes in fair values of derivatives designated as cash flow hedges [30.3] 221 (146) Reclassified to profit or loss (156) (46) Income taxes [14] (18) 57 Other comprehensive income from cash flow hedges 47 (135) Changes in fair values of available-for-sale financial assets [20] 52 – Reclassified to profit or loss (76) – Income taxes [14] 16 (2) Other comprehensive income from available-for-sale financial assets (8) (2) Changes in exchange differences recognized on translation of operations outside the eurozone (737) 1,384 Reclassified to profit or loss – – Other comprehensive income from exchange differences (737) 1,384 Other comprehensive income that may be reclassified subsequently to profit or loss (698) 1,247 Effects of changes in scope of consolidation (1) – Total other comprehensive income1 643 (2,291) of which attributable to non-controlling interest (14) 11 of which attributable to Bayer AG stockholders 657 (2,302) Total comprehensive income 3,829 1,152 of which attributable to non-controlling interest (17) 28 of which attributable to Bayer AG stockholders 3,846 1,124 1 total changes recognized outside profit or loss

	Note	Dec. 31, 2013	Dec. 31, 2014
		€ million	€ million
Noncurrent assets
Goodwill	[17]	9,862	16,168
Other intangible assets	[17]	8,914	15,653
Property, plant and equipment	[18]	10,015	11,428
Investments accounted for using the equity method	[19]	203	223
Other financial assets	[20]	1,203	1,107
Other receivables	[23]	496	447
Deferred taxes	[14]	1,596	2,981
		32,289	48,007
Current assets
Inventories	[21]	7,129	8,478
Trade accounts receivable	[22]	7,569	9,097
Other financial assets	[20]	779	723
Other receivables	[23]	1,476	1,488
Claims for income tax refunds		413	588
Cash and cash equivalents		1,662	1,853
		19,028	22,227
Total assets		51,317	70,234
Equity	[24]
Capital stock of Bayer AG		2,117	2,117
Capital reserves of Bayer AG		6,167	6,167
Other reserves		12,434	11,822
Equity attributable to Bayer AG stockholders		20,718	20,106
Equity attributable to non-controlling interest		86	112
		20,804	20,218
Noncurrent liabilities
Provisions for pensions and other post-employment benefits	[25]	7,368	12,236
Other provisions	[26]	1,977	2,016
Financial liabilities	[27]	5,590	18,484
Other liabilities	[29]	362	1,088
Deferred taxes	[14]	1,193	689
		16,490	34,513
Current liabilities
Other provisions	[26]	4,727	4,912
Financial liabilities	[27]	3,441	3,376
Trade accounts payable	[28]	4,473	5,363
Income tax liabilities	[26.1]	101	63
Other liabilities	[29]	1,281	1,789
		14,023	15,503
Total equity and liabilities		51,317	70
	Note	2013	2014
		€ million	€ million
Income after income taxes		3,186	3,443
Income taxes		1,021	1,082
Financial result		727	981
Income taxes paid or accrued		(1,644)	(1,315)
Depreciation, amortization and impairments		2,896	2,936
Change in pension provisions		(249)	(337)
(Gains) losses on retirements of noncurrent assets		(105)	30
Gross cash flow		5,832	6,820
Decrease (increase) in inventories		(608)	(741)
Decrease (increase) in trade accounts receivable		(751)	(1,094)
(Decrease) increase in trade accounts payable		389	518
Changes in other working capital, other non-cash items		309	307
Net cash provided by (used in) operating activities (net cash flow)	[33]	5,171	5,810
Cash outflows for additions to property, plant, equipment and intangible assets		(2,157)	(2,371)
Cash inflows from sales of property, plant, equipment and other assets		153	143
Cash inflows from divestitures		79	304
Cash inflows from (outflows for) noncurrent financial assets		204	(10)
Cash outflows for acquisitions less acquired cash		(1,082)	(13,545)
Interest and dividends received		125	107
Cash inflows from (outflows for) current financial assets		97	(167)
Net cash provided by (used in) investing activities	[34]	(2,581)	(15,539)
Dividend payments		(1,574)	(1,739)
Issuances of debt		9,078	27,584
Retirements of debt		(9,697)	(15,746)
Interest paid including interest-rate swaps		(550)	(541)
Interest received from interest-rate swaps		212	179
Cash outflows for the purchase of additional interests in subsidiaries		(4)	(1)
Net cash provided by (used in) financing activities	[35]	(2,535)	9,736
Change in cash and cash equivalents due to business activities		55	7
Cash and cash equivalents at beginning of year		1,698	1,662
Change in cash and cash equivalents due to changes in scope of consolidation		–	–
Change in cash and cash equivalents due to exchange rate movements		(91)	184
Cash and cash equivalents at end of year		1,662	1,853

Five-Year Summary

	2010	2011	2012	2013	2014
	€ million	€ million	€ million	€ million	€ million
Bayer Group
Sales	35,088	36,528	39,741	40,157	42,239
Sales outside Germany	87.4%	87.3%	88.3%	87.9%	88.2%
EBIT1	2,730	4,149	3,928	4,934	5,506
EBIT before special items2	4,452	5,025	5,639	5,773	5,944
EBITDA2	6,286	6,918	6,916	7,830	8,442
EBITDA before special items2	7,101	7,613	8,280	8,401	8,812
Income before income taxes	1,721	3,363	3,176	4,207	4,525
Income after income taxes	1,310	2,472	2,453	3,186	3,443
Earnings per share (€)3	1.57	2.99	2.91	3.86	4.14
Core earnings per share (€)	4.19	4.83	5.30	5.61	6.02
Noncurrent assets	33,188	32,697	32,308	32,289	48,007
of which goodwill and other intangible assets	20,163	19,455	18,757	18,776	31,821
of which property, plant and equipment	9,835	9,823	9,898	10,015	11,428
Current assets	18,318	20,068	19,010	19,028	22,227
Inventories	6,104	6,368	6,991	7,129	8,478
Receivables and other current assets	9,374	11,846	10,321	10,237	11,896
Cash and cash equivalents	2,840	1,770	1,698	1,662	1,853
Financial liabilities	11,833	11,679	9,530	9,031	21,860
Noncurrent	9,944	7,995	6,962	5,590	18,484
Current	1,889	3,684	2,568	3,441	3,376
Interest expense – net	(499)	(335)	(252)	(355)	(356)
Return on equity	6.9%	13.0%	13.0%	16.2%	16.8%
Gross cash flow4	4,771	5,172	4,556	5,832	6,820
Capital expenditures (total)	1,621	1,666	1,929	2,157	2,371
Depreciation and amortization	2,571	2,521	2,641	2,611	2,713
Research and development expenses	3,053	2,932	3,013	3,406	3,574
Equity including non-controlling interest (total)	18,896	19,271	18,551	20,804	20,218
Capital stock	2,117	2,117	2,117	2,117	2,117
Reserves	16,779	17,154	16,434	18,687	18,101
Net income	1,301	2,470	2,403	3,189	3,426
Non-controlling interest	63	59	100	86	112
Liabilities (total)	32,610	33,494	32,767	30,513	50,016
Total assets	51,506	52,765	51,318	51,317	70,234
Equity ratio	36.7%	36.5%	36.1%	40.5%	28.8%
Bayer AG
Net income	1,245	1,125	889	2,498	2,454
Allocation to (withdrawal from) retained earnings	5	(239)	(682)	761	593
Total dividend payment	1,240	1,364	1,571	1,737	1,861
Dividend per share (€)	1.50	1.65	1.90	2.10	2.25
Employees
Number of employees5(Dec. 31)	111,400	111,800	110,000	112,400	118,900
Personnel expenses (including pension expenses) (€ million)	8,099	8,726	9,194	9,430	9,845
Proportion of women in senior management (%)	21	22	23	25	26
Number of nationalities in the Group Leadership Circle	21	22	23	31	35
Proportion of employees with health insurance (%)	94	94	94	95	96
Proportion of employees covered by collective agreements on pay and conditions (%)	55	54	53	54	52
Safety
Recordable Incident Rate for Bayer employees (RIR)	0.62	0.56	0.49	0.47	0.43
Lost Time Recordable Incident Rate for Bayer employees (LTRIR)	0.34	0.31	0.27	0.26	0.22
Loss of Primary Containment Incident Rate (LoPC-IR)6	–	–	0.38	0.35	0.23
Number of transport incidents	8	7	6	11	12
Environmental Protection
Direct greenhouse gas emissions (CO2 equivalents in million t)7	4.80	4.23	4.24	4.09	4.02
Indirect greenhouse gas emissions (CO2 equivalents in million t)7	3.70	3.92	4.12	4.29	4.70
Volatile organic compounds (VOC) (thousand t/a)8	2.54	2.69	2.60	2.27	2.12
Ozone-depleting substances (ODS) (t/a)9	20.77	16.31	16.28	15.65	14.79
Total organic carbon (TOC) (thousand t/a)	1.42	1.50	1.42	1.53	1.20
Total phosphorus in wastewater (thousand t/a)	0.09	0.08	0.15	0.11	0.10
Total nitrogen in wastewater (thousand t/a)	0.49	0.53	0.70	0.69	0.76
Hazardous waste generated (thousand t/a)	354	474	603	467	487
Hazardous waste landfilled (thousand t/a)	56	122	175	53	65
Water use (million m³/a)	474	411	384	361	350
Primary energy consumption (petajoules/a)10	51.63	50.10	49.05	47.58	45.57
Secondary energy consumption (petajoules/a)10	34.08	34.85	34.14	33.27	39.74
Energy efficiency (MWh/t)11	3.77	3.63	3.50	3.44	3.37
2013 figures restated; figures for 2010-2012 as last reported  1 EBIT = earnings before financial result and taxes 2 For definition see Combined Management Report, Chapter 16.2 “Calculation of EBIT(DA) Before Special Items.” 3 Earnings per share as defined in IAS 33 = net income divided by the average number of shares. For details see Note [16] to the consolidated financial statements.  4 For definition see Combined Management Report, Chapter 16.5 “Liquidity and Capital Expenditures of the Bayer Group.” 5 Full-time equivalents 6 LoPC-IR: rate of incidents in which chemicals leak from their primary container, such as pipelines, pumps, tanks or drums, per 200,000 working hours in areas relevant to plant safety. LoPC-IR has been recorded since 2012. 7 Portfolio-adjusted in accordance with the Greenhouse Gas Protocol 8 Volatile organic compounds (VOC) excluding methane 9 Ozone-depleting substances (ODS) in CFC-11 equivalents 10 1 petajoule = 1015 joules 11 Energy efficiency: quotient of total energy consumption and manufactured sales volume. For MaterialScience, only manufactured sales volumes that also form the basis for calculating MaterialScience-specific emissions are taken into account.

Sumber :

http://www.pantonashare.com/4701-perkembangan-pt-bayer-indonesia

http://www.annualreport2014.bayer.com/en/income-statements.aspx